Derivation and Validation of a Genotype-Guided Warfarin Dosing Model in a Mixed Arab Population.

Genotype-guided warfarin dosing model (*VKORC1*, *CYP2C9*) validated in an Arab population

This study derives and validates a VKORC1/CYP2C9 genotype-guided warfarin dosing model specifically adapted to a mixed Arab population. Existing international models (Gage et al.) were developed on cohorts underrepresenting Arab patients. The derived model shows improved dosing precision compared to Gage in this population, with implications for anticoagulation initiation.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Warfarin remains widely used in Arab countries where direct anticoagulants have limited access. A validated dosing model in this population has immediate practical utility — and highlights that PGx cannot rely solely on European or North American cohort data.

Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10